Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

The article recommends three high-yielding dividend stocks for investors concerned about market volatility: AbbVie (3.3% yield), Chevron (3.8% yield), and Vici Properties (6.3% yield). All three stocks demonstrated resilience during the 2022 market downturn and offer strong fundamentals with consistent dividend payments.

Eli Lilly announced positive Phase 3 trial results for Jaypirca (pirtobrutinib), marking the fourth successful study for the blood cancer treatment. The BRUIN CLL-322 trial showed significant improvement in progression-free survival when combined with venetoclax and rituximab in patients with chronic lymphocytic leukemia. The company plans to submit results for label expansion later this year. Head-to-head data also demonstrated Jaypirca's competitive advantage over Johnson & Johnson's Imbruvica.

With S&P 500 dividend yields at historic lows of 1.2%, the article highlights three Dividend King stocks offering superior yields: AbbVie (3.20%), Procter & Gamble (2.91%), and Coca-Cola (2.66%). Despite AbbVie facing competition from a new rival drug, all three companies demonstrate strong cash generation, reliable dividend growth, and resilient business models that make them attractive for income investors.

Three companies are standing out in 2026 by aggressively raising dividends backed by strong fundamentals: Comfort Systems USA is capitalizing on AI data center infrastructure demand with a 35.3% five-year dividend growth rate; AbbVie maintains a solid 3.3% yield with 6.8% growth supported by blockbuster drugs; and Monolithic Power Systems is growing dividends 25%+ annually while benefiting from data center and automotive semiconductor demand.

The SLE and LN market is projected to grow from $2.4 billion in 2024 to $5.9 billion by 2034 (9.6% CAGR), driven by 10 late-stage pipeline drugs offering improved safety and efficacy over current generic treatments. However, growth faces headwinds from biosimilar competition and high treatment costs limiting adoption rates.

The atopic dermatitis market across seven major markets (US, France, Germany, Italy, Spain, UK, Japan) is projected to grow from $8.5 billion in 2023 to $21.5 billion by 2033, with a CAGR of 9.8%. Growth will be driven by seven late-stage pipeline drugs, expanded treatment options across all age groups and severities, and novel mechanisms of action including JAK inhibitors and IL-inhibiting biologics.

The global atopic dermatitis market is expected to grow from $10.8 billion in 2023 to $26.2 billion by 2033, driven by seven late-stage pipeline agents, expanded treatment options across demographics, and high treatment rates in key markets. The market will grow at a CAGR of 9.3% over the forecast period.

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

Johnson & Johnson is highlighted as an exceptional dividend stock for retirees, boasting a 63-year dividend-increase streak as a Dividend King. The diversified healthcare company combines pharmaceutical and medical device businesses, with an AAA credit rating ensuring dividend stability. However, its 2.2% yield, while double the S&P 500's 1.1%, falls short of the 4% target many dividend investors seek.

With inflation concerns resurfacing and the Federal Reserve pausing rate cuts, investors can combat inflation through dividend stocks yielding over 3%. Three Dividend Aristocrats—Amcor, Chevron, and AbbVie—each with 25+ consecutive years of dividend increases, offer reliable income streams that can outpace inflation while providing potential capital appreciation.

Red Spruce Capital increased its position in the Invesco BulletShares 2028 Corporate Bond ETF (BSCS) by 235,496 shares worth approximately $4.84 million in Q1 2026, bringing the holding to 3.67% of the fund's AUM. The purchase is part of a deliberate bond ladder strategy across 2027, 2028, and 2029 BulletShares ETFs, prioritizing income visibility and capital preservation with a 4.3% yield.